| Item Type | Name |
|
Concept
|
Hepatitis Delta Virus
|
|
Concept
|
Hepatitis B Surface Antigens
|
|
Concept
|
Hepatitis B virus
|
|
Concept
|
Hepatitis D
|
|
Concept
|
Hepatitis C Antibodies
|
|
Concept
|
Hepatitis, Autoimmune
|
|
Concept
|
Hepatitis B
|
|
Concept
|
Hepatitis C
|
|
Concept
|
Hepatitis C, Chronic
|
|
Academic Article
|
Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin.
|
|
Academic Article
|
Long-term outcomes after treatment with interferon and ribavirin in HCV patients.
|
|
Academic Article
|
Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.
|
|
Academic Article
|
Naives, nonresponders, relapsers: who is there left to treat?
|
|
Academic Article
|
Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40KD) and ribavirin.
|
|
Academic Article
|
Use of immune function test in monitoring immunosuppression in liver transplant recipients.
|
|
Academic Article
|
Hepatitis C virus: a critical appraisal of new approaches to therapy.
|
|
Academic Article
|
Sticker shock and the price of new therapies for hepatitis C: is it worth it?
|
|
Academic Article
|
Preparing for the uncertain yet inevitable: off-label combinations of antiviral agents in hepatitis C virus.
|
|
Academic Article
|
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
|
|
Academic Article
|
Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era.
|
|
Academic Article
|
HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape.
|
|
Academic Article
|
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
|
|
Academic Article
|
ACG Clinical Guideline: Liver Disease and Pregnancy.
|
|
Academic Article
|
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
|
|
Academic Article
|
Generic medications for hepatitis C.
|
|
Academic Article
|
Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials.
|
|
Academic Article
|
Management of hepatitis B virus.
|
|
Academic Article
|
Characterization of nonrapid virologic response patients infected with HCV genotype 1 who may relapse after standard therapy with peginterferon plus ribavirin.
|
|
Academic Article
|
Hepatitis C: management of side effects in the era of direct-acting antivirals.
|
|
Academic Article
|
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With?Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
|
|
Academic Article
|
Lack of Efficacy of Pegylated Interferon Monotherapy for Hepatitis C in Patients With End-Stage Renal Disease on Dialysis.
|
|
Academic Article
|
Updates on hepatitis C virus therapy in the direct-acting antiviral era.
|
|
Academic Article
|
Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment.
|
|
Academic Article
|
A pregnant patient with a positive hepatitis B surface antigen.
|
|
Academic Article
|
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
|
|
Academic Article
|
Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy.
|
|
Academic Article
|
Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy.
|
|
Academic Article
|
Concomitant proton pump inhibitor use does not reduce the efficacy of elbasvir/grazoprevir: A pooled analysis of 1,322 patients with hepatitis C infection.
|
|
Academic Article
|
Hepatitis C Virus Infection Care Pathway-A Report From the American Gastroenterological Association Institute HCV Care Pathway Work Group.
|
|
Academic Article
|
Potential consequences of healthcare recommendations: a focus on the U.S. Preventive Services Task Force.
|
|
Academic Article
|
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
|
|
Academic Article
|
A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study.
|
|
Academic Article
|
Report from the International Conference on Viral Hepatitis - 2017.
|
|
Academic Article
|
Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States.
|
|
Academic Article
|
Liver Diseases During Pregnancy.
|
|
Academic Article
|
Pangenotypic regimens and the next generation hepatitis C virus therapy.
|
|
Academic Article
|
Considering direct-acting antivirals to cure hepatitis C virus during pregnancy: is this the last treatment frontier?
|
|
Academic Article
|
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
|
|
Academic Article
|
HCV in Women and Pregnancy.
|
|
Academic Article
|
Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma.
|
|
Academic Article
|
Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.
|
|
Academic Article
|
Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS?CO13 HEPAVIH)".
|
|
Academic Article
|
Chronic Viral Hepatitis: Current Management and Future Directions.
|
|
Academic Article
|
Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States.
|
|
Academic Article
|
Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis.
|
|
Academic Article
|
Estimating the Year Each State in the United States Will Achieve the World Health Organization's Elimination Targets for Hepatitis?C.
|
|
Academic Article
|
Changing epidemiology, implications, and recommendations for hepatitis C in women of childbearing age and during pregnancy.
|
|
Academic Article
|
Patient-reported outcomes 12?months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study.
|
|
Academic Article
|
Willingness to participate in research among black patients with liver disease: A national cross-sectional study.
|
|
Academic Article
|
Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: A Patient-Friendly Summary of the 2019 AASLD Guidelines.
|
|
Academic Article
|
Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019.
|
|
Academic Article
|
Sustained Impact of the Coronavirus Disease 2019 Pandemic on Hepatitis C Virus Treatment Initiations in the United States.
|
|
Academic Article
|
Patients With Autoimmune Hepatitis and Nonalcoholic Fatty Liver Disease: Characteristics, Treatment, and Outcomes.
|
|
Academic Article
|
Hepatocellular Carcinoma and Hepatitis Delta Virus.
|
|
Academic Article
|
What Is the Real Epidemiology of Hepatitis D Virus and Why so Many Mixed Messages?
|